noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

DeCA - Defense Commissary Agency

Commissaries worldwide extend sale on select turkeys through December
Northrop Grumman Corporation

Northrop Grumman and IHI AEROSPACE Collaborate to Advance Global[...]
Northrop Grumman Corporation

Northrop Grumman to Produce High Explosive Proximity for the U.S. Army

Healthcare

Foghorn Therapeutics Inc.

12/04/2025 | Press release | Distributed by Public on 12/04/2025 06:00

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 3, 2025, the Board of Directors of Foghorn Therapeutics Inc. (the "Company") appointed Jeff Sacher as Treasurer and interim Chief Financial Officer ("CFO"), effective immediately. The Company is continuing its search for a permanent CFO.

The Company previously entered into an agreement with Danforth Advisors, LLC ("Danforth") pursuant to which Danforth provides strategic and financial consulting services to the Company. In addition to those services, the parties have agreed that Mr. Sacher, a CFO at Danforth, will provide interim CFO services to the Company. The Company will pay Danforth an agreed upon hourly rate for such services and will reimburse Danforth for expenses.

Mr. Sacher, age 60, is a 35-year veteran of the biotechnology and investment banking industries. He has served as a CFO at Danforth, a consultancy firm specializing in working with life sciences companies, since May 2022. Prior to his tenure at Danforth, Mr. Sacher had served as a senior investment banker for several investment banks. Mr. Sacher has an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in biology from Cornell University. Mr. Sacher has no family relationships with any of the executive officers or directors of the Company. Other than as described herein, there are no arrangements or understandings between Mr. Sacher and any other person pursuant to which he was appointed as an officer of the Company.

Foghorn Therapeutics Inc. published this content on December 04, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 04, 2025 at 12:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]